The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.
 
Léa Mercier
No Relationships to Disclose
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Edouard Auclin
No Relationships to Disclose
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Emily Alouani
No Relationships to Disclose
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Frank Sinicrope
Employment - MedVal (I)
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Guardant Health; Roche
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems. (Inst)
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); Gilead Sciences (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Marie Dutherage
No Relationships to Disclose
 
Anthony Turpin
No Relationships to Disclose
 
Thibault Mazard
Honoraria - Takeda
Consulting or Advisory Role - Galapagos NV; Merck Serono; Pierre Fabre; SERVIER
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Pierre Fabre; Sanofi
 
Francesco Sclafani
Honoraria - Amgen; Merck; Roche; SERVIER
Consulting or Advisory Role - Amal Therapeutics; Bayer; Bristol Myers Squibb; Dragonfly Therapeutics; GlaxoSmithKline; Nordic Bioscience
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Merck; Roche; SERVIER
(OPTIONAL) Uncompensated Relationships - Secretary of the EORTC Gastrointestinal Tract Cancer Group
 
Priya Jayachandran
No Relationships to Disclose
 
Javier Ros Montañá
Honoraria - Amgen
Speakers' Bureau - Sanofi
Travel, Accommodations, Expenses - Amgen; Amgen; Merck; Pierre Fabre; SERVIER
 
Lola Jade Palmieri
No Relationships to Disclose
 
Rosine Guimbaud
Honoraria - Amgen; Bayer; BMS; Esteve; MSD
Consulting or Advisory Role - BMSi; MSD Oncology; Pierre Fabre
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis; Merck; MSD Oncology; Pierre Fabre
 
Julien Taieb
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BMS; Boehringer Ingelheim; Brenus Pharma; Merck KGaA; MSD; natera; Novartis; Pierre Fabre; PROSKOPE; sanofi; SERVIER; takeda
Speakers' Bureau - Amgen; Merck; MSD; Pierre Fabre; SERVIER
 
Simon Pernot
No Relationships to Disclose